Comparative Pharmacology
Head-to-head clinical analysis: FLUOROMETHOLONE versus OTOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOROMETHOLONE versus OTOCORT.
FLUOROMETHOLONE vs OTOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce phospholipase A2 inhibitory proteins, thereby reducing prostaglandin and leukotriene synthesis. Exhibits anti-inflammatory, antipruritic, and vasoconstrictive effects.
Otocort is a combination product containing hydrocortisone (a corticosteroid), neomycin (an aminoglycoside antibiotic), and polymyxin B (a polymyxin antibiotic). Hydrocortisone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane permeability by binding to lipopolysaccharides.
1-2 drops of 0.1% suspension in conjunctival sac 2-4 times daily; severe cases: every 4 hours initially, then taper. Ointment: 0.5 inch ribbon 1-3 times daily.
1-2 drops into affected ear(s) twice daily; otic route.
None Documented
None Documented
Clinical Note
moderateFluorometholone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin."
Clinical Note
moderateFluorometholone + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin."
Clinical Note
moderateFluorometholone + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life: 1.3–2.2 hours; However, the pharmacodynamic half-life (duration of adrenal suppression) is longer (~24–36 hours) due to receptor-mediated effects.
Hydrocortisone: plasma half-life 1.5-2 hours, biological half-life 8-12 hours due to intracellular receptor binding. Neomycin: terminal half-life 2-4 hours in patients with normal renal function; may prolong to 12-24 hours in renal impairment. Polymyxin B: terminal half-life 6-8 hours in normal renal function; significantly prolonged in renal failure (up to 2-3 days). Clinical context: Topical/otic application yields negligible systemic concentrations, so half-life is relevant only if significant absorption occurs (e.g., damaged tympanic membrane).
Renal (primarily as metabolites): ~70%; Fecal: ~20%; Unchanged in urine: <5%
Otocort is a combination product containing hydrocortisone, neomycin, and polymyxin B. The corticosteroid component undergoes hepatic metabolism with renal excretion of metabolites (<5% unchanged). Neomycin is minimally absorbed (3-6% from intact skin, higher from wounds) and excreted renally as unchanged drug (30-50%) and metabolites. Polymyxin B is not significantly absorbed through intact skin or tympanic membrane; systemic absorption negligible. Renal excretion of polymyxin B is slow (40-60% over 72 hours) via glomerular filtration. Fecal elimination accounts for <5% of absorbed dose for all components.
Category A/B
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid
Fluorometholone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Trovafloxacin."